ReviewJournal of natural medicines2026
Matrine and oxymatrine: a comprehensive review of multitarget mechanisms and therapeutic potential.
Review in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
In recent years, research of matrine (MAT) and oxymatrine (OMT) has shifted from merely discovering pharmacological activities to exploring mechanisms, expanding new indications, and improving formulations. However, comparative analyses of their similarities and differences remain limited. Beyond their well-known functions in cancer treatment-such as regulating non-coding RNAs, preventing metastasis, and triggering apoptosis and ferroptosis-these compounds also show notable immunomodulatory effects, particularly in synergizing with immune checkpoint inhibitors to enhance tumor responsiveness. Furthermore, they show efficacy in inflammatory and autoimmune diseases (e.g., colitis, psoriasis, encephalomyelitis), neuroprotection, cardioprotection, and anti‑fibrosis. To overcome limitations such as hepatotoxicity and poor bioavailability, significant progress has been made in the structural modification of MAT and in the advanced formulation of OMT, thereby enhancing potency, selectivity, and targeted delivery. This review systematically consolidates recent advances in their multitarget mechanisms and expanding their therapeutic landscape. It also provides a unified mechanism overview and highlights the transformation strategy. These collective efforts will improve our understanding of MAT and OMT, offering a valuable reference for the further development of these natural products into modern therapeutics.
Indexed as
Identifiers
42319640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.